Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Seyoung Koo, Kondapa Naidu Bobba, Mi Young Cho, Hye Sun Park, Miae Won, Nithya Velusamy, Kwan Soo Hong, Sankarprasad Bhuniya, Jong Seung Kim

Research output: Contribution to journalArticle

Abstract

A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

Original languageEnglish
Pages (from-to)4648-4655
Number of pages8
JournalACS Applied Bio Materials
Volume2
Issue number10
DOIs
Publication statusPublished - 2019 Oct 21

Fingerprint

Prodrugs
Tumors
Fluorescence
Chemical activation
Fluorophores
Labeling
Neoplasms
Cells
Molecules
Monitoring
Theranostic Nanomedicine
Therapeutics
Pharmaceutical Preparations
Biotin
Hypoxia

Keywords

  • antitumor
  • drug targeting
  • hypoxia
  • prodrug
  • theranostic

ASJC Scopus subject areas

  • Biomaterials
  • Chemistry(all)
  • Biomedical Engineering
  • Biochemistry, medical

Cite this

Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors. / Koo, Seyoung; Bobba, Kondapa Naidu; Cho, Mi Young; Park, Hye Sun; Won, Miae; Velusamy, Nithya; Hong, Kwan Soo; Bhuniya, Sankarprasad; Kim, Jong Seung.

In: ACS Applied Bio Materials, Vol. 2, No. 10, 21.10.2019, p. 4648-4655.

Research output: Contribution to journalArticle

Koo, S, Bobba, KN, Cho, MY, Park, HS, Won, M, Velusamy, N, Hong, KS, Bhuniya, S & Kim, JS 2019, 'Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors', ACS Applied Bio Materials, vol. 2, no. 10, pp. 4648-4655. https://doi.org/10.1021/acsabm.9b00722
Koo S, Bobba KN, Cho MY, Park HS, Won M, Velusamy N et al. Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors. ACS Applied Bio Materials. 2019 Oct 21;2(10):4648-4655. https://doi.org/10.1021/acsabm.9b00722
Koo, Seyoung ; Bobba, Kondapa Naidu ; Cho, Mi Young ; Park, Hye Sun ; Won, Miae ; Velusamy, Nithya ; Hong, Kwan Soo ; Bhuniya, Sankarprasad ; Kim, Jong Seung. / Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors. In: ACS Applied Bio Materials. 2019 ; Vol. 2, No. 10. pp. 4648-4655.
@article{b6454637382f4c62bb34e306acdcd020,
title = "Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors",
abstract = "A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.",
keywords = "antitumor, drug targeting, hypoxia, prodrug, theranostic",
author = "Seyoung Koo and Bobba, {Kondapa Naidu} and Cho, {Mi Young} and Park, {Hye Sun} and Miae Won and Nithya Velusamy and Hong, {Kwan Soo} and Sankarprasad Bhuniya and Kim, {Jong Seung}",
year = "2019",
month = "10",
day = "21",
doi = "10.1021/acsabm.9b00722",
language = "English",
volume = "2",
pages = "4648--4655",
journal = "ACS Applied Bio Materials",
issn = "2576-6422",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

AU - Koo, Seyoung

AU - Bobba, Kondapa Naidu

AU - Cho, Mi Young

AU - Park, Hye Sun

AU - Won, Miae

AU - Velusamy, Nithya

AU - Hong, Kwan Soo

AU - Bhuniya, Sankarprasad

AU - Kim, Jong Seung

PY - 2019/10/21

Y1 - 2019/10/21

N2 - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

AB - A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

KW - antitumor

KW - drug targeting

KW - hypoxia

KW - prodrug

KW - theranostic

UR - http://www.scopus.com/inward/record.url?scp=85073170478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073170478&partnerID=8YFLogxK

U2 - 10.1021/acsabm.9b00722

DO - 10.1021/acsabm.9b00722

M3 - Article

AN - SCOPUS:85073170478

VL - 2

SP - 4648

EP - 4655

JO - ACS Applied Bio Materials

JF - ACS Applied Bio Materials

SN - 2576-6422

IS - 10

ER -